Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* ECOG 0 or 1~* Primary or metastatic tumor onfirmed as triple negative~* Measurable disease per RECIST version 1.1~* normal organ function, including bone marrow function, renal function, liver function, and cardiac function~* Two or more prior chemotherapy~* signed and dated an informed consent form~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breast feeding~* ECOG score ≧2~* Uncontrolled medical problems~* Hepatic, renal, or bone marrow dysfunction as detailed above~* Concurrent malignancy or history of other malignancy within the last five years except as noted above~* Patients were unable or unwilling to comply with program requirements

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib 125 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).